Epigenetic Regulation of normal hematopoiesis and its dysregulation in myeloid neoplasia


2012


Agrawal-Singh S, Isken F, Agelopoulos K, Klein HU, Thoennissen NH, Koehler G, Hascher A, Bäumer N, Berdel WE, Thiede C, Ehninger G, Becker A, Schlenke P, Wang Y, McClelland M, Krug U, Koschmieder S, Büchner T, Yu DY, Singh SV, Hansen K, Serve H, Dugas M, Müller-Tidow C. Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood. 2012;119(10):2346-2357. PMID:22207736

Hackanson B, Rimmele L, Benkißer M, Abdelkarim M, Fliegauf M, Jung M, Lübbert M.(2012). HDAC6 as a target for antileukemic drugs in acute myeloid leukemia. Leuk Res. [Epub ahead of print] PMID:22464548

Herglotz J., Kuvardina O.N., Kolodziej, S., Kumar, A., Hussong, H., Grez, M., Lausen, J.(2012). Histone arginine methylation keeps RUNX1 target genes in an intermediate state. Oncogene. Jul 9. doi: 10.1038/onc.2012.274. PMID:22777353

Kaufmann KB, Gründer A, Hadlich T, Wehrle J, Gothwal M, Bogeska R, Wagner JM, Jung M, Günther T, Schüle R, Rambaldi A, Pahl HL. (2012). A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J. Exp. Med. PMID:22231305

Lübbert M, Rüter BH, Claus R, Schmoor C, Schmid M, Germing U, Kuendgen A, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, Heil G, Hackanson B, Deschler B, Döhner K, Hagemeijer A, Wijermans PW, Döhner H. (2012). A multicenter phase II trial of continued Decitabine as first-line treatment of older AML patients judged unfit for induction chemotherapy. Haematologica. PMID:22058219

Pham TH, Benner C, Lichtinger M, Schwarzfischer L, Hu Y, Andreesen R, Chen W, Rehli M. (2012). Dynamic epigenetic enhancer signatures reveal key transcription factors associated with monocytic differentiation states. Blood. PMID:22550342

Schenk T, Chen WC, Göllner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, Casero RA, Jr., Marton L, Woster P, Minden MD, Dugas M, Wang JC, Dick JE, Müller-Tidow C, Petrie K, Zelent A. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012;18(4):605-611. PMID:22406747

Stolfa DA, Stefanachi A, Gajer JM (née Wagner), Nebbioso A, Altucci L, Cellamare S, Jung M, Carotti A. (2012). Design, synthesis and biological evaluation of 2-aminobenzanilide derivatives as potent and selective HDAC inhibitors. ChemMedChem. [Epub ahaead of print] PMID:22628266


2011


Benedikt A, Baltruschat S, Scholz B, Bursen A, Arrey TN, Meyer B, Varagnolo L, Müller AM, Karas M, Dingermann T, Marschalek R. (2011) The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia, 25: 135-144. PMID:21030982

Bocker MT, Hellwig I, Breiling A, Eckstein V, Ho AD, Lyko F. (2011). Genome-wide promoter DNA methylation dynamics of human hematopoietic progenitor cells during differentiation and aging. Blood 117, e182-189. PMID:21427290

Claus R, Hackanson B, Poetsch AR, Zucknick M, Sonnet M, Blagitko-Dorfs N, Hiller J, Wilop S, Brümmendorf TH, Galm O, Platzbecker U, Byrd JC, Döhner K, Döhner H, Lübbert M, Plass C. Quantitative analyses of DAPK1 methylation in AML and MDS. Int J Cancer, [Epub ahead of print]. PMID:21918973

Duque-Afonso J, Berg T, Heidenreich O, Lübbert M. (2011). The HDAC class I specific inhibitor Entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. Oncogene 30:3062-72 PMID:21577204

Ghani S, Riemke P, Schönheit J, Lenze D, Stumm J, Hoogenkamp M, Lagendijk A, Heinz S, Bonifer C, Bakkers J, Abdelilah-Seyfried S, Hummel M, Rosenbauer F. (2011). Macrophage development from hematopoietic stem cells requires PU.1 coordinated microRNA expression. Blood 118:2275-2284. PMID:21730352

Hagemann S, Heil O, Lyko F, Brueckner B. (2011). Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS ONE 6: e17388. PMID:21408221

Krais AM, Park YJ, Plass C, Schmeiser HH. (2011). Determination of genomic 5-hydroxymethyl-2'-deoxycytidine in human DNA by capillary electrophoresis with laser induced fluorescence. Epigenetics 6:560-565. PMID:21593596

Leddin M, Perrod C, Hoogenkamp M, Ghani S, Assi S, Heinz S, Wilson NK, Follows G, Schönheit J, Vockentanz L, Mosamam A, Chen W, Tenen DG, Westhead DR, Göttgens B, Bonifer C, Rosenbauer F. (2011). Two distinct auto-regulatory loops operate at the PU.1 locus in B cells and myeloid cells. Blood 117:2827-2838. PMID:21239694

Monroe SC, Joa SY, Sandersa DS, Basrura V, Elenitoba-Johnsona KS, Slany Rk, Hess JL. (2011). MLL-AF9 alters the dynamic association of transcriptional regulators with leukemogenic target genes, Exp.Hematol, 39:77-86. PMID:20854876

Olk-Batz C, Poetsch AR, Nöllke P, Claus R, Zucknick M, Sandrock I, Witte T, Strahm B, Hasle H, Zecca M, Stary J, Bergstraesser E, De Moerloose B, Trebo M, van den Heuvel-Eibrink MM, Wojcik D, Locatelli F, Plass C, Niemeyer CM, Flotho C. (2011). Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia (JMML) with poor outcome. Blood, 117:4871-4880. PMID:21406719

Park YJ, Claus R, Weichenhan D, Plass C. (2011). Genomie-wide epidenetic modifications in cancer (Review). Prog Drug Res, 67:25-49. PMID:21141723

Poetsch AR, Plass C. (2011). Transcriptional regulation by DNA methylation (Review). Cancer Treat Rev, 37 Suppl 1:S8-12. PMID:21601364

Schlimme S, Hauser AT, Carafa V, Heinke R, Stolfa DA, Cellamare S, Carotti A, Altucci L, Jung M, Sippl W. (2011). Carbamate prodrug concept for hydroxamate HDAC inhibitors. ChemMedChem. 6:1193-1198. PMID:21416613

Sienerth AR, Scheuermann C, Galmiche A, Rapp UR, Becker M. (2011) Polycomb group protein Bmi1 negatively regulates IL-10 expression in activated macrophages. Immunol Cell Biol, 89: 812–816. PMID:21221124

Teichler S., Illmer T., Roemhild J., Ovcharenko D., Stiewe T., Neubauer A. (2011) MicroRNA29a regulates the expression of the nuclear oncogene Ski. Blood, 118(7):1899-902. PMID:21685371

Walenda T, Bokermann G, Ferreria MV, Piroth D, Hieronymus T, Neuss-Stein S, Zenke M, Ho AD, Müller AM and Wagner W. (2011) Synergistic effects of growth factors and mesenchymal stromal cells for expansion of hematopoietic stem and progenitor cells. Exp. Hematol, 39: 617-628. PMID:21356269

Wlodarski MW, Mötter J, Gorr TA, Olk-Batz C, Hasle H, Dworzak M, Niemeyer CM, Flotho C. (2011). Abnormal promoter DNA methylation in juvenile myelomonocytic leukemia is not caused by mutation in DNMT3A. Blood 118: 4490-4491. PMID:22021454


2010


Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, Jäger E, Lübbert M. (2010). The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk. Res. 34:899-905. PMID:20381863

Gebhard C, Benner C, Ehrich M, Schwarzfischer L, Schilling E, Klug M, Dietmaier W, Thiede C, Holler E, Andreesen R et al. (2010). General transcription factor binding at CpG islands in normal cells correlates with resistance to de novo DNA methylation in cancer cells. Cancer Res 70(4): 1398-1407. PMID:20145141

International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, Kusada J, Lane DP, Laplace F, Youyong L, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, et al.(2010) International network of cancer genome projects. Nature, 464:993–998. PMID:20393554

Klug M, Heinz S, Gebhard C, Schwarzfischer L, Krause SW, Andreesen R, Rehli M. (2010). Active DNA demethylation in human postmitotic cells correlates with activating histone modifications, but not transcription levels. Genome Biol 11(6): R63. PMID:20565882

Lausen J, Pless O, Leonard F, Kuvardina ON, Koch B, Leutz A. (2010) Targets of the Tal1 transcription factor in erythrocytes: E2 ubiquitin conjugase regulation by Tal1. J Biol Chem, 285(8): 5338 – 46. PMID:20028976

Mah N, Wang Y, Mrowka R, Rosenbauer F, Adjaye J, Andrade-Navarro MA. (2010). Die Entwicklungsuhr zurückdrehen. Systembiologie.de. 2, 15-19. pdf

Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Sakamoto KM, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel PG, Heinzmann A, Schneider M, Stary J, van den Heuvel-Eibrink MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, Loh ML. (2010). Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 42: 794-800. PMID:20694012

Slany RK. (2010). When speed matters: Leukemogenic transformation by MLL fusion proteins. Cell Cycle, 9(13). PMID:20543578

Vockentanz L, Bröske AM, and Rosenbauer F. (2010). Uncovering a unique role for DNA methylation in hematopoietic and leukemic stem cells. Cell Cycle 9:640-641. PMID:20107327

Wagner JM, Hackanson B, Lübbert M, Jung M. (2010). Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenetics 1:117-136. PMID:21258646

Wichmann C, Becker Y, Chen-Wichmann L, Vogel V, Vojtkova A, Herglotz J, Moore S, Koch J, Lausen J, Mäntele W, Gohlke H, Grez M. (2010) Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity. Blood, 116(4): 603 – 13. PMID:20430957

Wichmann C, Grez M, Lausen J. (2010) Molecular Targeting of Aberrant Transcription Factors in Leukemia: Strategies for RUNX1/ETO. Current Drug Targets, 11(9): 1181 – 91. PMID:20583973


2009


Bröske AM, Vockentanz L, Kharazi S, Huska M, Mancini E, Scheller M, Enns A, Prinz M, Jaenisch R, Nerlov C, Leutz A, Andrade-Navarro MA, Jacobsen SEW, Rosenbauer F. (2009). DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nature Genetics 41: 1207-1215. PMID:19801979

Bruns I, Czibere A, Fischer JC, Roels F, Cadeddu R-P, Buest S, Bruennert D, Huenerlituerkoglu AN, Stoecklein NH, Singh R, Zerbini LF, Jäger M, Kobbe G, Gattermann N, Kronenwett R, Brors B, Haas R. (2009) The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia, 23:892–899. PMID:19158832

Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, Plass C, Niemeyer CM, Lübbert M. (2009). The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on gene expression in acute myeloid leukemia cells. Leukemia 23:1019-28. PMID:19194470

Furlan I, Batz C, Flotho C, Mohr B, Lübbert M, Suttorp M, Niemeyer CM. (2009). Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood 113: 2867-2868. PMID:19299654

Müller D, Garcia-Cuellar MP, Bach C, Buhl S, Mäthner E, and Slany RK. (2009). Misguided Transcriptional Elongation Causes Mixed Lineage Leukemia, PLOS Biology, 7(11):e1000249. PMID:19956800


2008


Pless O, Kowenz-Leutz E, Knoblich M, Lausen J, Beyermann M, Walsh MJ, Leutz A. (2008) G9a-mediated lysine methylation alters the function of CCAAT/enhancer-binding protein-beta. J. Biol. Chem. 283(39): 26357-63. PMID:18647749

Teichler S., Schlenk RF., Strauch K., Hagner NM., Ritter M., Neubauer A. (2008) Expression of the nuclear oncogene Ski in patients with acute myeloid leukemia treated with all-trans retinoic acid. Haematologica, 93(7):1105-7. PMID:18508800.


2007


Müller D, Bach C, Zeisig D, Garcia-Cuellar MP, Monroe S, Sreekumar A, Zhou R, Nesvizhskii A, Chinnaiyan A, Hess JL, Slany RK. (2007). A Role for the MLL Fusion Partner ENL in Transcriptional Elongation and Chromatin Modification, Blood, 110: 4445-4454. PMID:17855633

Wei Y, Liu S, Lausen J, Cho S, Biris N, Kobayashi N, Wei Y, Yokoyama S, Werner MH. (2007) A TAF4-homology domain from the co-repressor Eight Twenty-one (ETO) is a docking platform for positive and negative regulators of transcription. Nat. Struct. Mol. Biol. 14(7): 653-661. PMID:17572682


2006


Gebhard C, Schwarzfischer L, Pham TH, Schilling E, Klug M, Andreesen R, Rehli M. (2006). Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res 66(12): 6118-6128. PMID:16778185

Lausen J, Liu S, Fliegauf M, Lubbert M, Werner MH. (2006) ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO. Oncogene 25(9): 1349-57. PMID:16247445

Ritter M., Kattmann D., Teichler S., Hartmann O., Samuelsson MK., Burchert A., Bach JP., Kim TD., Berwanger B., Thiede C., Jäger R., Ehninger G., Schäfer H., Ueki N., Hayman MJ., Eilers M., Neubauer A. (2006) Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia. Leukemia. 20(3):437-43. PMID:16424870.


2004


Lausen J, Cho S, Liu S, Werner MH. (2004) The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO. J. Biol. Chem. 279(47): 49281-8. PMID:15377655